Barry P Flannelly sold $293k of INCY
EVP & General Manager US at INCYTE CORP. 3,680 shares at an average of $79.68, traded Nov 6, 2024, filed Nov 8, 2024.
Score components
- +15RoleOfficer
- +14Trade size$293k at market
- 0Share of holdings soldSold 6.0% of holdings
- 0ClusterNo other insider selling within 14 days
- -15Exercise and sellShares came from an option exercise in the same filing
- -2010b5-1 planPre-scheduled under a 10b5-1 plan
What happened after comparable sells
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
This signal so far: 1m -8.9%, 3m -11.1%, 6m -29.3%.
Price around the trade, and since
From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™
Rows in this filing
Every transaction in Form 4 0000879169-24-000174, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Nov 6, 2024 | MOption exercise Common Stock10b5-1 | +1,424 | $72.27 | $103k | 59,466 | Nov 8, 2024 |
| Nov 6, 2024 | MOption exercise Common Stock10b5-1 | +2,256 | $68.62 | $155k | 61,722 | Nov 8, 2024 |
| Nov 6, 2024 | SOpen-market sale Common Stock10b5-1 | -1,424 | $82.00 | $117k | 60,298 | Nov 8, 2024 |
| Nov 6, 2024 | SOpen-market sale Common Stock10b5-1 | -2,256 | $78.21 | $176k | 58,042 | Nov 8, 2024 |
| Nov 6, 2024 | MOption exercise Employee Stock Option (right to buy)derivative10b5-1 | -1,424 | $0.00 | $0 | 0 | Nov 8, 2024 |
| Nov 6, 2024 | MOption exercise Employee Stock Option (right to buy)derivative10b5-1 | -2,256 | $0.00 | $0 | 0 | Nov 8, 2024 |
Related signals
Other insiders at INCYTE CORP and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 15Weak | INCYTE CORP | Pablo J Cagnoni President, Global Head of R&D | $2.8M 23,218 shares | -11% | |
| 0Weak | INCYTE CORP | Sheila A. Denton EVP & General Counsel | $122k 1,795 shares | -6% | |
| 38Weak | INCYTE CORP | Barry P Flannelly EVP & General Manager US | $1.3M 19,807 shares | -37% | |
| 0Weak | INCYTE CORP | Sheila A. Denton EVP & General Counsel | $42k 599 shares | -2% | |
| 15Weak | INCYTE CORP | Sheila A. Denton EVP & General Counsel | $1.0M 14,069 shares | -35% | |
| 24Weak | INCYTE CORP | Steven H Stein EVP & Chief Medical Officer | $898k 12,352 shares | -16% | |
| 12Weak | INCYTE CORP | Thomas Tray Principal Accounting Officer | $91k 1,300 shares | -5% | |
| 25Weak | INCYTE CORP | Vijay K Iyengar EVP, GMAPPS | $456k 6,043 shares | -16% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.